SCIENCE NEWS
Theory of Single Stem Cell for Blood Components Challenged
Components of the blood or hematopoietic system derive from stem cell subtypes rather than one single stem cell that gives rise to all the different kinds of blood cells equally. [Press release from the Baylor College of Medicine discussing the online prepublication in Cell Stem Cell]
Stem Cells: Home of HIV?
Human immunodeficiency virus (HIV) can infect bone marrow cells – including, possibly, hematopoietic stem cells, according to a study published online. [Press release from The Scientist discussing online prepublication in Nature Medicine]
|
|
CURRENT PUBLICATIONS
LABORATORY RESEARCH
HIV-1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs
Here researchers used CD34+ cells from infected people as well as in vitro studies of wild-type HIV to show infection and killing of CD34+ multipotent hematopoietic progenitor cells. [Nat Med]
Endothelial Cells Are Essential for the Self-Renewal and Repopulation of Notch-Dependent Hematopoietic Stem Cells
Researchers have developed angiogenic models to demonstrate that endothelial cell-derived angiocrine growth factors support in vitro self-renewal and in vivo repopulation of authentic long-term hematopoietic stem cells. [Cell Stem Cell]
Distinct Hematopoietic Stem Cell Subtypes Are Differentially Regulated by Transforming Growth Factor-Beta1
This study demonstrates definitive isolation of lineage-biased hematopoietic stem cells subtypes and contributes to the fundamental change in view that the hematopoietic system is maintained by a continuum of hematopoietic stem cells subtypes, rather than a functionally uniform pool. [Cell Stem Cell]
Hematopoietic Progenitor Cell Regulation by CD4+CD25+ T Cells
Together these findings illustrate that both recipient and donor regulatory T cells can influence hematopoietic progenitor cell activity post-transplant and that these cells can alter responses outside the adaptive and innate immune systems. [Blood]
Expression of the Cytoplasmic NPM1 Mutant (NPMc+) Causes the Expansion of Hematopoietic Cells in Zebrafish
These results are likely to be relevant to human NPMc+ acute myeloid leukemia, where the observed NPMc+ multilineage expression pattern implies transformation of a multipotent stem or progenitor cell. [Blood]
Rational Design of a Fully Active, Long-Acting PEGylated Factor VIII for Hemophilia A Treatment
Site-specifically PEGylated FVIII has the potential to be a long-acting prophylactic treatment while being fully efficacious for on-demand treatment for hemophilia A patients. [Blood]
Mutant Ikzf1, KrasG12D, and Notch1 Cooperate in T Lineage Leukemogenesis and Modulate Responses to Targeted Agents
Together, these studies identify a genetic pathway involving Ikzf1, KrasG12D, and Notch1 in T lineage leukemogenesis, reveal unexpected diversity in Ras-regulated signaling networks, and define biomarkers of drug responses that may inform treatment strategies. [Proc Natl Acad Sci USA]
SHIP1 Inhibition Increases Immunoregulatory Capacity and Triggers Apoptosis of Hematopoietic Cancer Cells
SHIP1 inhibitors represent a novel class of small molecules that have the potential to enhance allogeneic transplantation, boost blood cell production, and improve the treatment of hematologic malignancies. [J Immunol]
Congenic Mice Confirm That Collagen X Is Required for Proper Hematopoietic Development
These data support a model where endochondral ossification-specific collagen X contributes to the establishment of a hematopoietic niche at the chondro-osseous junction. [PLoS ONE]
CLINICAL RESEARCH
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
The purpose of this study was to determine the efficacy and toxicity of the combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia younger than age 65 years. [J Clin Oncol]
Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase
Recipients of allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase who remain in remission for at least 5 years have favorable subsequent long-term survival, and their mortality rates eventually approach those of the general population. [J Clin Oncol]
Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
To define prognostic factors impacting long-term outcomes of reduced-intensity conditioning regimens in patients older than age 40 years with acute myeloid leukemia in first complete remission or myelodysplastic syndrome and to determine the impact of age, researchers analyzed data from the Center for International Blood and Marrow Transplant Research. [J Clin Oncol]
|
|
INDUSTRY NEWS
Bayer Settles With Novartis Over Hemophilia-Treatment Patent
Bayer AG, Germany’s largest drugmaker, settled a lawsuit brought by Novartis AG and Novo Nordisk A/S that claimed Bayer infringed a patent related to treatment of the bleeding disorder hemophilia. [BusinessWeek]
Canadian Budget Light on New Research Dollars
Relief was the order of the day for Canadian scientists as the federal government brought down its fiscal blueprint for 2010-11. [ScienceInsider]
In Annual Rite, Chinese Science Showered with Riches
At the opening session of the National People’s Congress, officials announced that the science and technology budget will rise 8% to 163.3 billion RMB ($24 billion) in 2010. [ScienceInsider]
BMTbase™ Version 4 Released
STEMSOFT Software is pleased to announce the release of BMTbase™ version 4! Completely redesigned from the ground up using .NET technology, version 4 is a browser-based application allowing for easier user access, deployment and more robust database management and security. [STEMSOFT Software Press Release]
Food and Drug Administration Approves NerPharMa to Manufacture Cell Therapeutics’ Drug Pixantrone
Cell Therapeutics (CTI), Inc. announced that the U.S. Food and Drug Administration has completed its inspection of the facility at NerPharMa, which manufactures the CTI’s drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product. [Cell Therapeutics Press Release]
|
|
POLICY NEWS
Request for Information (RFI): To Solicit Input for the National Institute of General Medical Sciences (NIGMS) Strategic Plan for Training and Career Development (NOT-GM-10-102) [National Institutes of Health, United States]
Correction to Required Budget Component for PAR-09-084: Enhancing Developmental Biology Research at Undergraduate Institutions Academic Research Enhancement Award (R15) (NOT-HD-10-007) [National Institutes of Health, United States]
Clarification of Budget Form for PAR-09-092 Academic-Community Partnership Conference Series (U13) (NOT-HD-10-009) [National Institutes of Health, United States]
Recovery Act Limited Competition: The NIH Director’s American Recovery & Reinvestment Act Funded Pathfinder Award to Promote Diversity in the Scientific Workforce (DP4) (RFA-OD-10-013) [National Institutes of Health, United States]
Minority Access to Research Careers Undergraduate Student Training in Academic Research (U-STAR) National Research Service Award (NRSA) Institutional Research Training Grant (T34) (PAR-10-119) [National Institutes of Health, United States]
Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01) (PAR-10-126) [National Cancer Institute, United States]
Collaborative Research for Molecular and Genomic Studies of Behavior in Animal Models (R01) (PA-10-125) [National Institute of General Medical Sciences, United States]
Workshops, Meetings & Conferences (Biologics) DIA/FDA CDER/CBER Computational Science Annual Meeting, Posted [Food and Drug Administration, United States]
Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications; Availability [Food and Drug Administration, United States]
|
|
EVENTS
36th Annual Meeting of the European Group for Blood & Marrow Transplantation (EBMT)
March 21-24, 2010
Vienna, Austria
12th Biennial Canadian Blood and Marrow Transplant Group (CBMTG) Conference
April 7-10, 2010
Vancouver, Canada
American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States
International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States
XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany
Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States 52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit!
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
